Achillion Pharmaceuticals Up On Buyout Rumors

By | August 18, 2014

Scalper1 News

Achillion Pharmaceuticals (ACHN) stock touched an 18-month high for the second straight trading day on Monday, after Deutsche Bank upgraded the biotech startup and boosted price target on positive news about its new hepatitis drug. Achillion stock was up more than 2% in afternoon trading in the stock market today, near 9.50, after rising 9.6% on Friday. Achillion stock has risen 46% since mid-June, after Merck (MRK) announced that it would buy Scalper1 News

Scalper1 News